Amelia Nathania Dong
Overview
Explore the profile of Amelia Nathania Dong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
26
Followers
0
Related Specialties
Related Specialties
Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dong A, Ahemad N, Pan Y, Palanisamy U, Yiap B, Ong C
Drug Metab Bioanal Lett
. 2022 Jan;
15(1):51-63.
PMID: 35049443
Background: Genetic polymorphism of cytochrome P450 (CYP) contributes to variability in drug metabolism, clearance, and response. This study aimed to investigate the functional and molecular basis for altered ligand binding...
2.
Dong A, Tan B, Pan Y, Ong C
J Pharm Pharm Sci
. 2021 Feb;
24:94-112.
PMID: 33626316
Since the discovery of its role in vitamin D metabolism, significant progress has been made in the understanding of gene organisation, protein structure, catalytic function, and genetic polymorphism of cytochrome...
3.
Dong A, Ahemad N, Pan Y, Palanisamy U, Yiap B, Ong C
Curr Mol Pharmacol
. 2019 Nov;
13(3):233-244.
PMID: 31713493
Background: There is a large inter-individual variation in cytochrome P450 2C19 (CYP2C19) activity. The variability can be caused by the genetic polymorphism of CYP2C19 gene. This study aimed to investigate...
4.
Dong A, Ahemad N, Pan Y, Palanisamy U, Yiap B, Ong C
Naunyn Schmiedebergs Arch Pharmacol
. 2019 Apr;
392(8):1015-1029.
PMID: 31025144
One major source of inter-individual variability in drug pharmacokinetics is genetic polymorphism of the cytochrome P450 (CYP) genes. This study aimed to elucidate the enzyme kinetic and molecular basis for...
5.
Dong A, Tan B, Pan Y, Ong C
Clin Exp Pharmacol Physiol
. 2018 Jun;
45(10):991-1001.
PMID: 29858511
Over the past 2 decades, knowledge of the role and clinical value of pharmacogenetic markers has expanded so that individualized pre-emptive therapy based on genetic background of patients could be...
6.
Dong A, Pan Y, Palanisamy U, Yiap B, Ahemad N, Ong C
Appl Biochem Biotechnol
. 2018 Mar;
186(1):132-144.
PMID: 29524040
Genetic polymorphism of the cytochrome P450 (CYP) genes particularly affects CYP2D6 and CYP2C19 to a functionally relevant extent, and it is therefore crucial to elucidate the enzyme kinetic and molecular...
7.
Tan B, Pan Y, Dong A, Ong C
J Pharm Pharm Sci
. 2017 Nov;
20(1):319-328.
PMID: 29145931
In vitro and in silico models of drug metabolism are utilized regularly in the drug research and development as tools for assessing pharmacokinetic variability and drug-drug interaction risk. The use...